Which is better, CPRX or LMAT?

On the Buffett-Fit framework, LeMaitre Vascular, Inc. (LMAT) currently grades higher than CPRX — 77/100 (B grade) vs 69/100 (C). That said, "better" depends on which framework you trust — CPRX wins on Philip Fisher, Charlie Munger, and Terry Smith; LMAT wins on Warren Buffett, Benjamin Graham, Peter Lynch, and Joel Greenblatt. The full pillar breakdown is on this page.

Should I buy CPRX or LMAT?

This page is an educational comparison, not investment advice. Both CPRX and LMAT are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is CPRX better than LMAT for value investing?

On the Buffett-style value-investing framework, LMAT currently grades higher — 77/100 vs 69/100, a 8-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between CPRX and LMAT on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). CPRX currently scores 69/100 (C grade); LMAT scores 77/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, CPRX or LMAT?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. CPRX and LMAT are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, CPRX or LMAT?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are CPRX and LMAT both Healthcare stocks?

Yes — both Catalyst Pharmaceuticals, Inc. (CPRX) and LeMaitre Vascular, Inc. (LMAT) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this CPRX vs LMAT comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Catalyst Pharmaceuticals

LeMaitre Vascular

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

CPRX

Market cap

$3.83B

Sector

Healthcare

LMAT

LeMaitre Vascular

Market cap

$2.23B

Sector

Healthcare

Overall winner

LeMaitre Vascular LMAT

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	CPRX	LMAT	Winner
Warren Buffett	69C	77B	LMAT
Benjamin Graham	75B	89A	LMAT
Philip Fisher	87C	81C	CPRX
Peter Lynch	65B	67B	LMAT
Joel Greenblatt	42D	56D	LMAT
Charlie Munger	78B	68D	CPRX
Terry Smith	78B	69D	CPRX

Side-by-side metrics

Metric	CPRX	LMAT
Market cap	$3.83B	$2.23B
P/E (TTM)	17.3x	37.1x
EV/EBIT	11.9x	36.6x
ROIC (TTM)	19.67%	9.43%
Gross margin	82.32%	72.39%
Net margin	37.08%	24.35%
Revenue CAGR 5y	43.0%	12.75%
EPS CAGR 5y	46.49%	19.04%
Debt / Equity	0.0x	0.5x
Dividend yield	0.0%	0.84%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

CPRX leads on

Debt / Equity0.0xvs 0.5x+99%
Revenue CAGR 5y43.0%vs 12.75%+70%
EV/EBIT11.9xvs 36.6x+67%
EPS CAGR 5y46.49%vs 19.04%+59%

LMAT leads on

Dividend yield0.84%vs 0.0%+100%

More like CPRX

CPRX vs HALO CPRX vs RMD CPRX vs LLY CPRX vs UTHR CPRX vs HAE CPRX vs IDXX

More like LMAT

LMAT vs HALO LMAT vs RMD LMAT vs LLY LMAT vs UTHR LMAT vs HAE LMAT vs IDXX

Read the full Buffett-Brain analysis for CPRX Read the full Buffett-Brain analysis for LMAT

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Catalyst Pharmaceuticals

LeMaitre Vascular

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

CPRX

Catalyst Pharmaceuticals

Market cap

$3.83B

Sector

Healthcare

LMAT

LeMaitre Vascular

Market cap

$2.23B

Sector

Healthcare

Overall winner

LeMaitre Vascular LMAT

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	CPRX	LMAT	Winner
Warren Buffett	69C	77B	LMAT
Benjamin Graham	75B	89A	LMAT
Philip Fisher	87C	81C	CPRX
Peter Lynch	65B	67B	LMAT
Joel Greenblatt	42D	56D	LMAT
Charlie Munger	78B	68D	CPRX
Terry Smith	78B	69D	CPRX

Side-by-side metrics

Metric	CPRX	LMAT
Market cap	$3.83B	$2.23B
P/E (TTM)	17.3x	37.1x
EV/EBIT	11.9x	36.6x
ROIC (TTM)	19.67%	9.43%
Gross margin	82.32%	72.39%
Net margin	37.08%	24.35%
Revenue CAGR 5y	43.0%	12.75%
EPS CAGR 5y	46.49%	19.04%
Debt / Equity	0.0x	0.5x
Dividend yield	0.0%	0.84%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

CPRX leads on

Debt / Equity0.0xvs 0.5x+99%
Revenue CAGR 5y43.0%vs 12.75%+70%
EV/EBIT11.9xvs 36.6x+67%
EPS CAGR 5y46.49%vs 19.04%+59%

LMAT leads on

Dividend yield0.84%vs 0.0%+100%

More like CPRX

CPRX vs HALO CPRX vs RMD CPRX vs LLY CPRX vs UTHR CPRX vs HAE CPRX vs IDXX

More like LMAT

LMAT vs HALO LMAT vs RMD LMAT vs LLY LMAT vs UTHR LMAT vs HAE LMAT vs IDXX

Read the full Buffett-Brain analysis for CPRX Read the full Buffett-Brain analysis for LMAT

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.